89.5 A
Tesamorelin
Also known as: Egrifta
FDA Approved Unregulated — Sold as research chemical
Research Evidence 94.0/100
Safety Profile 85.0/100
24 Clinical Trials
Unknown: 3 PHASE4: 2 PHASE3: 2 PHASE2: 10 PHASE1: 2 NA: 5
- Growth Hormone Dynamics and Cardiac Steatosis in HIV Unknown Phase COMPLETED Massachusetts General Hospital
- Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Unknown Phase TERMINATED Theratechnologies
- Egrifta Replacement and Sleep Disordered Breathing Unknown Phase WITHDRAWN Johns Hopkins University
- Body Composition and Adipose Tissue in HIV PHASE4 COMPLETED Columbia University
- Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® PHASE4 TERMINATED Theratechnologies
Showing 5 of 24 trials.
18 Research Papers
- Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. J Mass Spectrom unknown
- Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal unknown
- Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. J Pharm Biomed Anal unknown
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract Review
- An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. J Pharm Biomed Anal unknown
Showing 5 of 18 papers by citation count.
FDA Data
Not FDA-Approved
Tesamorelin has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is Tesamorelin FDA approved?
No, Tesamorelin has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has Tesamorelin been studied in?
Tesamorelin has been studied in 24 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Tesamorelin?
Tesamorelin has a CheckPeptides trust score of 89.5/100 (grade: A). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- GHRH analogue
- Molecular Weight
- 5136.0 Da
- PubChem
- CID 16137828 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 94.0/100
Safety Profile 85.0/100
Evidence Summary
- Clinical Trials
- 24
- Research Papers
- 18
- Trust Score
- 89.5/100
- Grade
- A